Sorry MW I am not a regular subscriber of AFR.
I only came across the article after buying a copy today.
Key points:
1. Analyst speculating about licensing partners for Laninamivir for North America and Europe. Obvious partner is GSK but some anaylysts tipped Sanofi-Aventis.
2. BTA expects registration of the product 1Q 2010 in Japan.
3. 1 dose of Laninamivir = 2 doses x 5 days of Tamiflu.
4. BTA to return $20m to investors.
5. Analyst expects increased production of Relenza by GSK to deliver $108.7m in fiscal 2010.
A very positive article.
- Forums
- ASX - By Stock
- BTA
- flu drugs keep biota healthy - page 46 fin rev
flu drugs keep biota healthy - page 46 fin rev, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online